Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy

被引：3

作者：

Quinn, Nicola ^{[1
]}

Januszewski, Andrzej S. ^{[1
,3
]}

Brazionis, Laima ^{[3
]}

O'Connell, Rachel ^{[1
]}

Aryal, Nanda ^{[1
]}

O'Day, Justin ^{[4
]}

Scott, Russell ^{[5
]}

Mitchell, Paul ^{[2
]}

Jenkins, Alicia J. ^{[1
,3
]}

Keech, Anthony C. ^{[1
]}

机构：

[1] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[2] Univ Sydney, Clin Ophthalmol & Eye Hlth, Westmead Clin Sch, Sydney, NSW, Australia

[3] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia

[4] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Ophthalmol, Melbourne, Vic, Australia

[5] Christchurch Hosp, Lipid & Diabet Res Grp, Christchurch, New Zealand

来源：

INTERNAL MEDICINE JOURNAL | 2022年 / 52卷 / 04期

基金：

英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;

关键词：

diabetes; microvascular complication; diabetic retinopathy; retinal grading; VASCULAR CALIBER; VESSEL DIAMETERS; MELLITUS;

D O I：

10.1111/imj.15733

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Retinal vessel calibre metrics were evaluated at baseline and 2 years in a FIELD substudy (n = 208). Central retinal venule calibre was significantly reduced by fenofibrate and unchanged by placebo. Arteriole metrics did not change. Larger studies relating retinal vessel calibre to future diabetes complications and response to therapy are merited.

引用

页码：676 / 679

页数：4